Dergiler / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 10

Irritable Bowel Syndrome on Inflammatory Bowel Disease in Deep Remission: No Relation with Remission Deepening and Inflammation

Sayfa
870–878
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: IBS frequency among IBD patients with remission was in a substantial rate; these rates kept up with the process of deep remission and even complete mucosal healing and were irrelevant to inflammation.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: The aim of the study was to establish the frequency of irritable bowel syndrome (IBS) in patients with inflammatory bowel disease (IBD) in clinical, endoscopic, and histologic remission and in relation to both the depth of remission and inflammation markers.
📊
Temel Bulgular & Veri:Methods: Patients with ulcerative colitis (UC) and with Crohn’s disease (CD) in clinical remission for at least 6 months were enrolled in the study.
💡
Sonuç & Katkı:Conclusion: IBS frequency among IBD patients with remission was in a substantial rate; these rates kept up with the process of deep remission and even complete mucosal healing and were irrelevant to inflammation.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background: The aim of the study was to establish the frequency of irritable bowel syndrome (IBS) in patients with inflammatory bowel disease (IBD) in clinical, endoscopic, and histologic remission and in relation to both the depth of remission and inflammation markers. Methods: Patients with ulcerative colitis (UC) and with Crohn’s disease (CD) in clinical remission for at least 6 months were enrolled in the study. All of the patients underwent colonoscopy, and biopsy specimens were taken to evaluate endoscopic and histopathologic remission. Patients were evaluated according to Rome III criteria for IBS. Fecal calprotectin level and blood samples for C-reactive protein (CRP), sedimentation rate, and fibrinogen levels were studied. Results: IBS frequency was 20.9% in UC cases and 28.9% in CD cases in clinical remission. Rates with and without endoscopic remission in UC (20.5% vs. 22.2%, P = .727) and CD (25% vs. 33.3%, P = .837, respectively) were not different. Similarly, rates with and without histopathologic remission in UC (15.7% vs. 26.6%, P = .723), and CD (21.4% vs. 33.3%, P = .999) were not statistically different. Also, it was not related to inflammation markers. Conclusion: IBS frequency among IBD patients with remission was in a substantial rate; these rates kept up with the process of deep remission and even complete mucosal healing and were irrelevant to inflammation.

🔖

Bu Makaleye Atıf Yap

SEZGİN, O., BOZTEPE, B., ÜÇBİLEK, E., ALTINTAŞ, E., ÇELİKCAN, H. (2021). Irritable Bowel Syndrome on Inflammatory Bowel Disease in Deep Remission: No Relation with Remission Deepening and Inflammation. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 10, 870–878. https://ajindex.com/articles/408644

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016
  2. 65(3):408- 414. [CrossRef] 2. Li K, Strauss R, Marano C, et al. A simplified definition of histologic improvement in Ulcerative Colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post hoc analysis of three clinical trials. J Crohns Colitis. 2019
  3. 13(8):1025- 1035. [CrossRef] 3. Flores BM, O’Connor A, Moss AC. Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. Gastrointest Endosc. 2017
  4. 86(6):1006-1011.e8. [CrossRef] 4. Edwards JT, Radford-Smith GL, Florin TH. Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical characteristics. J Gastroenterol Hepatol. 2001
  5. 16(11):1235-1238. [CrossRef] 5. Siegel CA, MacDermott RP. Is chronic pain an extraintestinal manifestation of IBD? Inflamm Bowel Dis. 2009
  6. 15(5):769-771. [CrossRef] 6. Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis. 2006
  7. 12(1):38-46. [CrossRef] 7.Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. IBS-like symptoms in patients with inflammatory bowel disease in remission
  8. relationships with quality of life and coping behavior. Dig Dis Sci. 2004
  9. 49(3):469-474. [CrossRef] 8. Keohane J, O’Mahony C, O’Mahony L, et al. Irritable bowel syndrome- type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?. Am J Gastroenterol. 2010
  10. 105(8):1788, 1789-94. [CrossRef] 9. Quigley EMM. Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? Therap Adv Gastroenterol. 2016
  11. 9(2):199-212. [CrossRef] 10. Piche T, Ducrotté P, Sabate JM, et al. Impact of functional bowel symptoms on quality of life and fatigue in quiescent crohn disease and irritable bowel syndrome. Neurogastroenterol Motil. 2010
  12. 22(6):626-e174. [CrossRef] 11.Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease:systematic review and meta-analysis. Am J Gastroenterol. 2012
  13. 107(10):1474- 1482. [CrossRef] 12.Bryant RV, van Langenberg DR, Holtmann GJ, Andrew